Targeting the Enhanced Sensitivity of Radiotherapy in Cancer: Mechanisms, Applications, and Challenges

Abstract

Cancer is a major public health, societal, and economic challenge worldwide. According to Global Cancer Statistics 2022, it is estimated that by 2050, there will be 35 million new cancer cases globally. Although patient survival rates have improved through various therapeutic approaches, including surgery, chemotherapy, and radiotherapy, treatment efficacy remains limited once tumor metastasis occurs. Among various cancer treatment strategies, radiotherapy plays a crucial role. Along with surgery and chemotherapy, radiotherapy is a cost-effective single-modality treatment, accounting for approximately 5% of total cancer care costs. The use of radiosensitizing agents such as histone deacetylase inhibitors, 2-deoxy-d-glucose, enterolactone, and squalene epoxidase can enhance radiotherapy effectiveness. Recent radiosensitization methods involve physical stimuli and chemical radiosensitizers. However, improving their efficacy, durability, and overcoming radioresistance remain significant challenges. This review first introduces current applications of radiotherapy in cancer treatment, the molecular mechanisms underlying its anticancer effects, and its side effects. Second, it discusses the main types of radiosensitizers, their latest applications, and recent challenges in cancer treatment. Finally, it emphasizes on clinical trials of radiosensitizing agents and explores potential biomarkers for radiotherapy response in cancer. Multifunctional nanoparticles have shown greater clinical applicability than single-functional nanoparticles. Future research will focus on enhancing the drug-carrying capacity of nanomaterials to further improve radiotherapy outcomes.

Keywords

combination therapy / radiosensitization / radiosensitizers / radiotherapy

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229-263.

[2] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 12-49.

[3] R. Yang, B. Zhang, X. Fei, et al., “Bioinspired Micro- and Nanostructured Systems for Cancer Therapy,” MedComm 5, no. 12 (2024): e70025.

[4] N. Harbeck and M. Gnant, “Breast Cancer,” Lancet 389, no. 10074 (2017): 1134-1150.

[5] A. A. Hashmi, K. A. Hashmi, M. Irfan, et al., “Ki67 index in Intrinsic Breast Cancer Subtypes and Its Association With Prognostic Parameters,” BMC Research Res Notes 12, no. 1 (2019): 605.

[6] L. Zhao, M. Li, C. Shen, et al., “Nano-Assisted Radiotherapy Strategies: New Opportunities for Treatment of Non-Small Cell Lung Cancer,” Research (Wash D C) 7 (2024): 0429.

[7] G. P. Delaney and M. B. Barton, “Evidence-based Estimates of the Demand for Radiotherapy,” Clinical Oncology (Royal College of Radiologists (Great Britain)) 27, no. 2 (2015): 70-76.

[8] U. Ringborg, D. Bergqvist, B. Brorsson, et al., “The Swedish Council on Technology Assessment in Health Care (SBU) Systematic Overview of Radiotherapy for Cancer Including a Prospective Survey of Radiotherapy Practice in Sweden 2001-summary and Conclusions,” Acta Oncologica 42, no. 5-6 (2003): 357-365.

[9] V. Bhat, S. Pellizzari, A. L. Allan, et al., “Radiotherapy and Radiosensitization in Breast Cancer: Molecular Targets and Clinical Applications,” Critical Reviews in Oncology/Hematology 169 (2022): 103566.

[10] R. de Jong, J. Visser, N. van Wieringen, J. Wiersma, D. Geijsen, and A. Bel, “Feasibility of Conebeam CT-based Online Adaptive Radiotherapy for Neoadjuvant Treatment of Rectal Cancer,” Radiation oncology 16, no. 1 (2021): 136.

[11] A. E. Giuliano, K. K. Hunt, K. V. Ballman, et al., “Axillary Dissection vs no Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial,” Jama 305, no. 6 (2011): 569-575.

[12] T. J. Whelan, I. A. Olivotto, and M. N. Levine, “Regional Nodal Irradiation in Early-Stage Breast Cancer,” New England Journal of Medicine 373, no. 19 (2015): 1878-1879.

[13] L. B. Thorsen, B. V. Offersen, H. Danø, et al., “DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer,” Journal of Clinical Oncology 34, no. 4 (2016): 314-320.

[14] A. G. Waks and E. P. Winer, “Breast Cancer Treatment: A Review,” Jama 321, no. 3 (2019): 288-300.

[15] D. A. Palma, R. Olson, S. Harrow, et al., “Stereotactic Ablative Radiotherapy versus Standard of Care Palliative Treatment in Patients With Oligometastatic Cancers (SABR-COMET): A Randomised, Phase 2, Open-label Trial,” Lancet 393, no. 10185 (2019): 2051-2058.

[16] D. A. Palma, R. Olson, S. Harrow, et al., “Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial,” Journal of Clinical Oncology 38, no. 25 (2020): 2830-2838.

[17] J. Bernier, E. J. Hall, and A. Giaccia, “Radiation Oncology: A Century of Achievements,” Nature Reviews Cancer 4, no. 9 (2004): 737-747.

[18] Z. R. Zhou, Z. Z. Yang, X. L. Yu, and X. M. Guo, “Highlights on Molecular Targets for Radiosensitization of Breast Cancer Cells: Current Research Status and Prospects,” Cancer medicine 7, no. 7 (2018): 3110-3117.

[19] L. Gong, Y. Zhang, C. Liu, M. Zhang, and S. Han, “Application of Radiosensitizers in Cancer Radiotherapy,” International Journal of Nanomedicine 16 (2021): 1083-1102.

[20] M. E. Lomax, L. K. Folkes, and P. O'Neill, “Biological Consequences of Radiation-induced DNA Damage: Relevance to Radiotherapy,” Clinical Oncology (Royal College of Radiologists (Great Britain)) 25, no. 10 (2013): 578-585.

[21] K. Goričar, F. Dugar, V. Dolžan, and T. N. B. N. Marinko, “RAD51 and XRCC3 Polymorphisms as Potential Predictive Biomarkers of Adjuvant Radiotherapy Toxicity in Early HER2-Positive Breast Cancer,” Cancers (Basel) 14, no. 18 (2022): 4365.

[22] L. Cortesi, C. Piombino, and A. Toss, “Germline Mutations in Other Homologous Recombination Repair-Related Genes than BRCA1/2: Predictive or Prognostic Factors,” Journal of Personalized Medicine 11, no. 4 (2021): 245.

[23] C. Piombino and L. Cortesi, “Insights Into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors,” Cancers (Basel) 14, no. 11 (2022): 2804.

[24] V. Mladenova, E. Mladenov, M. Stuschke, and G. Iliakis, “DNA Damage Clustering After Ionizing Radiation and Consequences in the Processing of Chromatin Breaks,” Molecules (Basel, Switzerland) 27, no. 5 (2022): 1540.

[25] P. S. VanderVere-Carozza, N. S. Gavande, S. I. Jalal, et al., “In Vivo Targeting Replication Protein A for Cancer Therapy,” Frontiers in oncology 12 (2022): 826655.

[26] A. E. Vidal, S. Boiteux, I. D. Hickson, and J. P. Radicella, “XRCC1 coordinates the Initial and Late Stages of DNA Abasic Site Repair Through Protein-protein Interactions,” Embo Journal 20, no. 22 (2001): 6530-6539.

[27] N. Moullan, D. G. Cox, S. Angèle, P. Romestaing, J. P. Gérard, and J. Hall, “Polymorphisms in the DNA Repair Gene XRCC1, Breast Cancer Risk, and Response to Radiotherapy,” Cancer Epidemiology and Prevention Biomarkers 12, no. 11 Pt 1 (2003): 1168-1174.

[28] S. C. Sak, P. Harnden, C. F. Johnston, A. B. Paul, and A. E. Kiltie, “APE1 and XRCC1 Protein Expression Levels Predict Cancer-specific Survival Following Radical Radiotherapy in Bladder Cancer,” Clinical Cancer Research 11, no. 17 (2005): 6205-6211.

[29] H. Ryu, H. J. Kim, J. Y. Song, et al., “A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy,” International Journal of Molecular Sciences 20, no. 23 (2019): 6026.

[30] H. He, W. Yang, Y. Shi, et al., “Design and Synthesis of the First PARP-1 and Proteasome Dual Inhibitors to Treat Breast Cancer,” European Journal of Medicinal Chemistry 264 (2024): 115943.

[31] I. A. Voutsadakis and A. Stravodimou, “Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies,” Anticancer Research 43, no. 3 (2023): 967-981.

[32] K. Ni, G. Lan, Y. Song, Z. Hao, and W. Lin, “Biomimetic Nanoscale Metal-organic Framework Harnesses Hypoxia for Effective Cancer Radiotherapy and Immunotherapy,” Chemical Science 11, no. 29 (2020): 7641-7653.

[33] S. Wang, Z. Zhou, R. Hu, et al., “Metabolic Intervention Liposome Boosted Lung Cancer Radio-Immunotherapy via Hypoxia Amelioration and PD-L1 Restraint,” Advanced science (Weinheim) 10, no. 18 (2023): e2207608.

[34] R. Zhang, Y. Yang, W. Dong, et al., “D-mannose Facilitates Immunotherapy and Radiotherapy of Triple-negative Breast Cancer via Degradation of PD-L1,” PNAS 119, no. 8 (2022): e2114851119.

[35] Y. Xia, S. Shen, and I. M. Verma, “NF-κB, an Active Player in human Cancers,” Cancer immunology research 2, no. 9 (2014): 823-830.

[36] F. Tuğrul, C. Vejselova Sezer, and H. M. Kutlu, “Proapoptotic Effects of ceranib-2 in Combination With Radiation Therapy on human Breast Cancer Cells,” European Review for Medical and Pharmacological Sciences 28, no. 6 (2024): 2322-2328.

[37] O. Inanami, D. Iizuka, A. Iwahara, et al., “A Novel Anticancer Ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine, Enhances Radiation-induced Cell Death in Tumor Cells,” Radiation Research 162, no. 6 (2004): 635-645.

[38] J. Xie, Y. Li, K. Jiang, et al., “CDK16 Phosphorylates and Degrades p53 to Promote Radioresistance and Predicts Prognosis in Lung Cancer,” Theranostics 8, no. 3 (2018): 650-662.

[39] K. H. Vousden and C. Prives, “Blinded by the Light: The Growing Complexity of p53,” Cell 137, no. 3 (2009): 413-431.

[40] B. Ogretmen, “Sphingolipid Metabolism in Cancer Signalling and Therapy,” Nature Reviews Cancer 18, no. 1 (2018): 33-50.

[41] P. Santana, L. A. Peña, A. Haimovitz-Friedman, et al., “Acid Sphingomyelinase-deficient human Lymphoblasts and Mice Are Defective in Radiation-induced Apoptosis,” Cell 86, no. 2 (1996): 189-199.

[42] D. Sharma and G. J. Czarnota, “Involvement of Ceramide Signalling in Radiation-Induced Tumour Vascular Effects and Vascular-Targeted Therapy,” International Journal of Molecular Sciences 23, no. 12 (2022): 6671.

[43] H. Abdollahi, “Radiotherapy Dose Painting by Circadian Rhythm Based Radiomics,” Medical Hypotheses 133 (2019): 109415.

[44] N. Nelson, J. Lombardo, L. Matlack, et al., “Chronoradiobiology of Breast Cancer: The Time Is Now to Link Circadian Rhythm and Radiation Biology,” International Journal of Molecular Sciences 23, no. 3 (2022): 1331.

[45] D. Dadey, V. Kapoor, K. Hoye, et al., “Antibody Targeting GRP78 Enhances the Efficacy of Radiation Therapy in Human Glioblastoma and Non-Small Cell Lung Cancer Cell Lines and Tumor Models,” Clinical Cancer Research 23, no. 10 (2017): 2556-2564.

[46] H. Deng, Y. Chen, P. Li, et al., “PI3K/AKT/mTOR Pathway, Hypoxia, and Glucose Metabolism: Potential Targets to Overcome Radioresistance in Small Cell Lung Cancer,” Cancer Pathogenesis and Therapy 1, no. 1 (2023): 56-66.

[47] Z. Yang and D. J. Klionsky, “Mammalian Autophagy: Core Molecular Machinery and Signaling Regulation,” Current Opinion in Cell Biology 22, no. 2 (2010): 124-131.

[48] D. Hanahan and R. A. Weinberg, “Hallmarks of Cancer: The next Generation,” Cell 144, no. 5 (2011): 646-674.

[49] Q. Wu and D. Sharma, “Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy,” Cells 12, no. 8 (2023): 1156.

[50] M. D. Rybstein, J. M. Bravo-San Pedro, G. Kroemer, and L. Galluzzi, “The Autophagic Network and Cancer,” Nature Cell Biology 20, no. 3 (2018): 243-251.

[51] A. R. Young, M. Narita, M. Ferreira, et al., “Autophagy Mediates the Mitotic Senescence Transition,” Genes & development 23, no. 7 (2009): 798-803.

[52] N. Santana-Codina, J. D. Mancias, and A. C. Kimmelman, “The Role of Autophagy in Cancer,” Annual Review of Cancer Biology 1 (2017): 19-39.

[53] D. A. Gewirtz, “The Four Faces of Autophagy: Implications for Cancer Therapy,” Cancer Research 74, no. 3 (2014): 647-651.

[54] Y. Yang, Y. Yang, X. Yang, et al., “Autophagy and Its Function in Radiosensitivity,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 36, no. 6 (2015): 4079-4087.

[55] P. Hönscheid, K. Datta, and M. H. Muders, “Autophagy: Detection, Regulation and Its Role in Cancer and Therapy Response,” International Journal of Radiation Biology 90, no. 8 (2014): 628-635.

[56] L. Gao, H. Zheng, Q. Cai, and L. Wei, “Autophagy and Tumour Radiotherapy,” Advances in Experimental Medicine and Biology 1207 (2020): 375-387.

[57] X. H. Liang, S. Jackson, M. Seaman, et al., “Induction of Autophagy and Inhibition of Tumorigenesis by Beclin 1,” Nature 402, no. 6762 (1999): 672-676.

[58] C. Miracco, E. Cosci, G. Oliveri, et al., “Protein and mRNA Expression of Autophagy Gene Beclin 1 in human Brain Tumours,” International Journal of Oncology 30, no. 2 (2007): 429-436.

[59] S. Vega-Rubín-de-Celis, Z. Zou, Á. F. Fernández, et al., “Increased Autophagy Blocks HER2-mediated Breast Tumorigenesis,” PNAS 115, no. 16 (2018): 4176-4181.

[60] M. Li, J. Liu, S. Li, et al., “Autophagy-related 7 Modulates Tumor Progression in Triple-negative Breast Cancer,” Laboratory Investigation 99, no. 9 (2019): 1266-1274.

[61] R. Lock, S. Roy, C. M. Kenific, et al., “Autophagy Facilitates Glycolysis During Ras-mediated Oncogenic Transformation,” Molecular Biology of the Cell 22, no. 2 (2011): 165-178.

[62] P. Maycotte, C. M. Gearheart, R. Barnard, et al., “STAT3-mediated Autophagy Dependence Identifies Subtypes of Breast Cancer Where Autophagy Inhibition Can be Efficacious,” Cancer Research 74, no. 9 (2014): 2579-2590.

[63] Y. Wu, Y. Elshimali, M. Sarkissyan, H. Mohamed, S. Clayton, and J. V. Vadgama, “Expression of FOXO1 Is Associated With GATA3 and Annexin-1 and Predicts Disease-free Survival in Breast Cancer,” American Journal of Cancer Research 2, no. 1 (2012): 104-115.

[64] H. O. Habashy, E. A. Rakha, M. Aleskandarany, et al., “FOXO3a nuclear Localisation Is Associated With Good Prognosis in Luminal-Like Breast Cancer,” Breast Cancer Research and Treatment 129, no. 1 (2011): 11-21.

[65] N. Wen, Q. Lv, and Z. G. Du, “MicroRNAs Involved in Drug Resistance of Breast Cancer by Regulating Autophagy,” Journal of Zhejiang University Science B 21, no. 9 (2020): 690-702.

[66] N. S. Katheder, R. Khezri, F. O'Farrell, et al., “Microenvironmental Autophagy Promotes Tumour Growth,” Nature 541, no. 7637 (2017): 417-420.

[67] A. G. Smith and K. F. Macleod, “Autophagy, Cancer Stem Cells and Drug Resistance,” Journal of Pathology 247, no. 5 (2019): 708-718.

[68] D. M. Gwinn, D. B. Shackelford, D. F. Egan, et al., “AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint,” Molecular Cell 30, no. 2 (2008): 214-226.

[69] F. Nazio, M. Bordi, V. Cianfanelli, F. Locatelli, and F. Cecconi, “Autophagy and Cancer Stem Cells: Molecular Mechanisms and Therapeutic Applications,” Cell Death and Differentiation 26, no. 4 (2019): 690-702.

[70] X. Bai, J. Ni, J. Beretov, P. Graham, and Y. Li, “Triple-negative Breast Cancer Therapeutic Resistance: Where Is the Achilles' heel,” Cancer Letters 497 (2021): 100-111.

[71] L. Liu, A. V. Salnikov, N. Bauer, et al., “Triptolide Reverses Hypoxia-induced Epithelial-mesenchymal Transition and Stem-Like Features in Pancreatic Cancer by NF-κB Downregulation,” International Journal of Cancer 134, no. 10 (2014): 2489-2503.

[72] C. Michiels, “Physiological and Pathological Responses to Hypoxia,” American Journal of Pathology 164, no. 6 (2004): 1875-1882.

[73] S. Y. Tam, V. W. Wu, and H. K. Law, “Influence of Autophagy on the Efficacy of Radiotherapy,” Radiation oncology 12, no. 1 (2017): 57.

[74] T. Lu, Z. Zhu, J. Wu, et al., “DRAM1 regulates Autophagy and Cell Proliferation via Inhibition of the Phosphoinositide 3-kinase-Akt-mTOR-ribosomal Protein S6 Pathway,” Cell Communication and Signaling 17, no. 1 (2019): 28.

[75] D. Y. Lee, D. Arnott, and E. J. Brown, “Ubiquilin4 is an Adaptor Protein That Recruits Ubiquilin1 to the Autophagy Machinery,” Embo Reports 14, no. 4 (2013): 373-381.

[76] S. Sun, W. Zhang, Z. Cui, et al., “High Mobility Group Box-1 and Its Clinical Value in Breast Cancer,” OncoTargets and Therapy 8 (2015): 413-419.

[77] D. Averbeck and C. Rodriguez-Lafrasse, “Role of Mitochondria in Radiation Responses: Epigenetic, Metabolic, and Signaling Impacts,” International Journal of Molecular Sciences 22, no. 20 (2021): 11047.

[78] E. McCann, J. O'Sullivan, and S. Marcone, “Targeting Cancer-cell Mitochondria and Metabolism to Improve Radiotherapy Response,” Translational Oncology 14, no. 1 (2021): 100905.

[79] G. Li, X. Lin, X. Wang, et al., “Enhancing Radiosensitivity in Triple-negative Breast Cancer Through Targeting ELOB,” Breast Cancer (Tokyo, Japan) 31, no. 3 (2024): 426-439.

[80] C. Diepart, O. Karroum, J. Magat, et al., “Arsenic Trioxide Treatment Decreases the Oxygen Consumption Rate of Tumor Cells and Radiosensitizes Solid Tumors,” Cancer Research 72, no. 2 (2012): 482-490.

[81] N. Crokart, B. F. Jordan, C. Baudelet, et al., “Glucocorticoids Modulate Tumor Radiation Response Through a Decrease in Tumor Oxygen Consumption,” Clinical Cancer Research 13, no. 2 Pt 1 (2007): 630-635.

[82] T. Wu and Y. Dai, “Tumor Microenvironment and Therapeutic Response,” Cancer Letters 387 (2017): 61-68.

[83] L. Portella and S. Scala, “Ionizing Radiation Effects on the Tumor Microenvironment,” Seminars in Oncology 46, no. 3 (2019): 254-260.

[84] S. Demaria and S. C. Formenti, “Radiation as an Immunological Adjuvant: Current Evidence on Dose and Fractionation,” Frontiers in oncology 2 (2012): 153.

[85] T. C. Blair, S. Bambina, A. F. Alice, et al., “Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy,” Journal of Immunology 204, no. 12 (2020): 3416-3424.

[86] A. Filatenkov, J. Baker, A. M. Mueller, et al., “Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions,” Clinical Cancer Research 21, no. 16 (2015): 3727-3739.

[87] N. Shaverdian, A. E. Lisberg, K. Bornazyan, et al., “Previous Radiotherapy and the Clinical Activity and Toxicity of pembrolizumab in the Treatment of Non-small-cell Lung Cancer: A Secondary Analysis of the KEYNOTE-001 Phase 1 Trial,” The Lancet Oncology 18, no. 7 (2017): 895-903.

[88] V. E. Krisnawan, J. A. Stanley, J. K. Schwarz, and D. G. DeNardo, “Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights Into Stromal-Mediated Radioresistance,” Cancers (Basel) 12, no. 10 (2020): 2916.

[89] H. E. Barker, J. T. Paget, A. A. Khan, and K. J. Harrington, “The Tumour Microenvironment After Radiotherapy: Mechanisms of Resistance and Recurrence,” Nature Reviews Cancer 15, no. 7 (2015): 409-425.

[90] J. Xu, J. Escamilla, S. Mok, et al., “CSF1R signaling Blockade Stanches Tumor-infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer,” Cancer Research 73, no. 9 (2013): 2782-2794.

[91] D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan, et al., “Progenitor Cell Trafficking Is Regulated by Hypoxic Gradients Through HIF-1 Induction of SDF-1,” Nature Medicine 10, no. 8 (2004): 858-864.

[92] Y. Meng, M. A. Beckett, H. Liang, et al., “Blockade of Tumor Necrosis Factor Alpha Signaling in Tumor-associated Macrophages as a Radiosensitizing Strategy,” Cancer Research 70, no. 4 (2010): 1534-1543.

[93] S. A. Gerber, A. L. Sedlacek, K. R. Cron, S. P. Murphy, J. G. Frelinger, and E. M. Lord, “IFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor,” American Journal of Pathology 182, no. 6 (2013): 2345-2354.

[94] J. Zhang, S. Zhang, M. Liu, Z. Yang, and R. Huang, “Research Progress on Ferroptosis and Nanotechnology-Based Treatment in Triple-Negative Breast Cancer,” Breast Cancer (Dove Med Press) 16 (2024): 347-358.

[95] X. Liu, B. Luo, X. Wu, and Z. Tang, “Cuproptosis and Cuproptosis-related Genes: Emerging Potential Therapeutic Targets in Breast Cancer,” Biochimica et Biophysica Acta: Reviews on Cancer 1878, no. 6 (2023): 189013.

[96] C. Peitzsch, I. Kurth, L. Kunz-Schughart, M. Baumann, and A. Dubrovska, “Discovery of the Cancer Stem Cell Related Determinants of Radioresistance,” Radiotherapy and Oncology 108, no. 3 (2013): 378-387.

[97] C. W. Bleaney, H. Abdelaal, M. Reardon, et al., “Clinical Biomarkers of Tumour Radiosensitivity and Predicting Benefit From Radiotherapy: A Systematic Review,” Cancers (Basel) 16, no. 10 (2024): 1942.

[98] J. Boustani, M. Grapin, P. A. Laurent, L. Apetoh, and C. Mirjolet, “The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response,” Cancers (Basel) 11, no. 6 (2019): 860.

[99] R. Dayal, A. Singh, A. Pandey, and K. P. Mishra, “Reactive Oxygen Species as Mediator of Tumor Radiosensitivity,” Journal of Cancer Research and Therapeutics 10, no. 4 (2014): 811-818.

[100] P. Wardman, “Chemical Radiosensitizers for Use in Radiotherapy,” Clinical Oncology (Royal College of Radiologists (Great Britain)) 19, no. 6 (2007): 397-417.

[101] V. Ahire, A. Kumar, K. P. Mishra, and G. Kulkarni, “Ellagic Acid Enhances Apoptotic Sensitivity of Breast Cancer Cells to γ-Radiation,” Nutrition and Cancer 69, no. 6 (2017): 904-910.

[102] P. Tiwari and K. P. Mishra, “Flavonoids Sensitize Tumor Cells to Radiation: Molecular Mechanisms and Relevance to Cancer Radiotherapy,” International Journal of Radiation Biology 96, no. 3 (2020): 360-369.

[103] E. C. Wang, Y. Min, R. C. Palm, et al., “Nanoparticle Formulations of Histone Deacetylase Inhibitors for Effective Chemoradiotherapy in Solid Tumors,” Biomaterials 51 (2015): 208-215.

[104] P. Ortega, B. Gómez-González, and A. Aguilera, “Rpd3L and Hda1 Histone Deacetylases Facilitate Repair of Broken Forks by Promoting Sister Chromatid Cohesion,” Nature Communications 10, no. 1 (2019): 5178.

[105] P. Marks, R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly, “Histone Deacetylases and Cancer: Causes and Therapies,” Nature Reviews Cancer 1, no. 3 (2001): 194-202.

[106] Z. Zhu, M. Wu, J. Sun, et al., “Redox-sensitive Iodinated Polymersomes Carrying Histone Deacetylase Inhibitor as a Dual-functional Nano-radiosensitizer for Enhanced Radiotherapy of Breast Cancer,” Drug Delivery 28, no. 1 (2021): 2301-2309.

[107] S. Grant, C. Easley, and P. Kirkpatrick, “Vorinostat,” Nat Rev Drug Discovery 6, no. 1 (2007): 21-22.

[108] H. Zeng, J. Qu, N. Jin, et al., “Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer,” Cancer Cell 30, no. 3 (2016): 459-473.

[109] C. Shen, M. Li, Y. Duan, et al., “HDAC Inhibitors Enhance the Anti-tumor Effect of Immunotherapies in Hepatocellular Carcinoma,” Frontiers in immunology 14 (2023): 1170207.

[110] M. Duvic and M. Dimopoulos, “The Safety Profile of Vorinostat (suberoylanilide hydroxamic acid) in Hematologic Malignancies: A Review of Clinical Studies,” Cancer Treatment Reviews 43 (2016): 58-66.

[111] A. Suraweera, K. J. O'Byrne, and D. J. Richard, “Combination Therapy with Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi,” Frontiers in oncology 8 (2018): 92.

[112] H. J. Cho, S. Y. Kim, K. H. Kim, et al., “The Combination Effect of Sodium Butyrate and 5-Aza-2'-deoxycytidine on Radiosensitivity in RKO Colorectal Cancer and MCF-7 Breast Cancer Cell Lines,” World Journal of Surgical Oncology 7 (2009): 49.

[113] W. Feng, D. Cai, B. Zhang, G. Lou, and X. Zou, “Combination of HDAC Inhibitor TSA and Silibinin Induces Cell Cycle Arrest and Apoptosis by Targeting Survivin and cyclinB1/Cdk1 in Pancreatic Cancer Cells,” Biomedicine & Pharmacotherapy 74 (2015): 257-264.

[114] S. Iwahashi, M. Shimada, T. Utsunomiya, et al., “Histone Deacetylase Inhibitor Augments Anti-tumor Effect of Gemcitabine and Pegylated Interferon-α on Pancreatic Cancer Cells,” International Journal of Clinical Oncology 16, no. 6 (2011): 671-678.

[115] H. Hu, Q. Wang, Y. Zhang, et al., “Effects of a Novel HDAC6-selective Inhibitor's Radiosensitization on Cancer Cells,” Molecular Biology Reports 51, no. 1 (2024): 1151.

[116] N. Makita, I. Ninomiya, T. Tsukada, et al., “Inhibitory Effects of Valproic Acid in DNA Double-strand Break Repair After Irradiation in Esophageal Squamous Carcinoma Cells,” Oncology Reports 34, no. 3 (2015): 1185-1192.

[117] R. L. Aft, F. W. Zhang, and D. Gius, “Evaluation of 2-deoxy-D-glucose as a Chemotherapeutic Agent: Mechanism of Cell Death,” British Journal of Cancer 87, no. 7 (2002): 805-812.

[118] M. Oladghaffari, A. Shabestani Monfared, A. Farajollahi, et al., “MLN4924 and 2DG Combined Treatment Enhances the Efficiency of Radiotherapy in Breast Cancer Cells,” International Journal of Radiation Biology 93, no. 6 (2017): 590-599.

[119] M. Luo, L. Chen, J. Zheng, et al., “Mitigation of Radiation-induced Pulmonary Fibrosis by Small-molecule Dye IR-780,” Free Radical Biology and Medicine 164 (2021): 417-428.

[120] M. J. McCann, I. R. Rowland, and N. C. Roy, “Anti-proliferative Effects of Physiological Concentrations of Enterolactone in Models of Prostate Tumourigenesis,” Molecular Nutrition & Food Research 57, no. 2 (2013): 212-224.

[121] M. J. McCann, I. R. Rowland, and N. C. Roy, “The Anti-proliferative Effects of Enterolactone in Prostate Cancer Cells: Evidence for the Role of DNA Licencing Genes, Mi-R106b Cluster Expression, and PTEN Dosage,” Nutrients 6, no. 11 (2014): 4839-4855.

[122] B. Bigdeli, B. Goliaei, N. Masoudi-Khoram, et al., “Enterolactone: A Novel Radiosensitizer for human Breast Cancer Cell Lines Through Impaired DNA Repair and Increased Apoptosis,” Toxicology and Applied Pharmacology 313 (2016): 180-194.

[123] H. Ge, Y. Zhao, X. Shi, et al., “Squalene Epoxidase Promotes the Proliferation and Metastasis of Lung Squamous Cell Carcinoma Cells Though Extracellular Signal-regulated Kinase Signaling,” Thorac Cancer 10, no. 3 (2019): 428-436.

[124] Z. Sui, J. Zhou, Z. Cheng, and P. Lu, “Squalene Epoxidase (SQLE) Promotes the Growth and Migration of the Hepatocellular Carcinoma Cells,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 36, no. 8 (2015): 6173-6179.

[125] Z. Hong, T. Liu, L. Wan, et al., “Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy,” Cancer Research 82, no. 7 (2022): 1298-1312.

[126] L. Wei, X. Wang, M. Luo, H. Wang, H. Chen, and C. Huang, “The PAD4 Inhibitor GSK484 Enhances the Radiosensitivity of Triple-negative Breast Cancer,” Human & Experimental Toxicology 40, no. 7 (2021): 1074-1083.

[127] X. Tu, M. M. Kahila, Q. Zhou, et al., “ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer,” Molecular Cancer Therapeutics 17, no. 11 (2018): 2462-2472.

[128] K. X. Zhou, L. H. Xie, X. Peng, et al., “CXCR4 antagonist AMD3100 Enhances the Response of MDA-MB-231 Triple-negative Breast Cancer Cells to Ionizing Radiation,” Cancer Letters 418 (2018): 196-203.

[129] K. Honma, K. Iwao-Koizumi, F. Takeshita, et al., “RPN2 gene Confers Docetaxel Resistance in Breast Cancer,” Nature Medicine 14, no. 9 (2008): 939-948.

[130] Z. Habibi-Kelishomi, B. Goliaei, and A. Nikoofar, “Butein Combined With Radiotherapy Enhances Radioresponse of Gastric Cancer Cell by Impairing DNA Damage Repair,” Biochemical and Biophysical Research Communications 570 (2021): 35-40.

[131] N. Jiang, A. I. Doseff, and E. Grotewold, “Flavones: From Biosynthesis to Health Benefits,” Plants (Basel) 5, no. 2 (2016): 27.

[132] T. Y. Wang, Q. Li, and K. S. Bi, “Bioactive Flavonoids in Medicinal Plants: Structure, Activity and Biological Fate,” Asian Journal of Pharmaceutical Sciences 13, no. 1 (2018): 12-23.

[133] A. Puthli, R. Tiwari, and K. P. Mishra, “Biochanin A Enhances the Radiotoxicity in Colon Tumor Cells in Vitro,” Journal of Environmental Pathology, Toxicology and Oncology 32, no. 3 (2013): 189-203.

[134] X. Liu, C. Sun, X. Jin, et al., “Genistein Enhances the Radiosensitivity of Breast Cancer Cells via G₂/M Cell Cycle Arrest and Apoptosis,” Molecules (Basel, Switzerland) 18, no. 11 (2013): 13200-13217.

[135] M. Y. Park, Y. Kim, S. E. Ha, et al., “Function and Application of Flavonoids in the Breast Cancer,” International Journal of Molecular Sciences 23, no. 14 (2022): 7732.

[136] W. Yan, X. Ma, X. Zhao, and S. Zhang, “Baicalein Induces Apoptosis and Autophagy of Breast Cancer Cells via Inhibiting PI3K/AKT Pathway in Vivo and Vitro,” Drug Design, Development and Therapy 12 (2018): 3961-3972.

[137] S. Khozooei, S. Veerappan, I. Bonzheim, S. Singer, C. Gani, and M. Toulany, “Fisetin Overcomes Non-targetability of Mutated KRAS Induced YB-1 Signaling in Colorectal Cancer Cells and Improves Radiosensitivity by Blocking Repair of Radiation-induced DNA Double-strand Breaks,” Radiotherapy and Oncology 188 (2023): 109867.

[138] Y. Zhao, H. Huang, C. H. Jia, et al., “Apigenin Increases Radiosensitivity of Glioma Stem Cells by Attenuating HIF-1α-mediated Glycolysis,” Medical Oncology 38, no. 11 (2021): 131.

[139] Y. Du, C. Jia, Y. Liu, Y. Li, J. Wang, and K. Sun, “Isorhamnetin Enhances the Radiosensitivity of A549 Cells through Interleukin-13 and the NF-κB Signaling Pathway,” Frontiers in pharmacology 11 (2020): 610772.

[140] K. D. Setchell and C. Clerici, “Equol: History, Chemistry, and Formation,” Journal of Nutrition 140, no. 7 (2010): 1355S-1362S.

[141] I. R. Rowland, H. Wiseman, T. A. Sanders, H. Adlercreutz, and E. A. Bowey, “Interindividual Variation in Metabolism of Soy Isoflavones and Lignans: Influence of Habitual Diet on Equol Production by the Gut Microflora,” Nutrition and Cancer 36, no. 1 (2000): 27-32.

[142] B. Taghizadeh, L. Ghavami, A. Nikoofar, and B. Goliaei, “Equol as a Potent Radiosensitizer in Estrogen Receptor-positive and -negative human Breast Cancer Cell Lines,” Breast Cancer (Tokyo, Japan) 22, no. 4 (2015): 382-390.

[143] P. Liczbiński and B. Bukowska, “Molecular Mechanism of Amygdalin Action in Vitro: Review of the Latest Research,” Immunopharmacology and Immunotoxicology 40, no. 3 (2018): 212-218.

[144] M. A. El-Desouky, A. A. Fahmi, I. Y. Abdelkader, and K. M. Nasraldin, “Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc,” Anti-cancer agents in medicinal chemistry 20, no. 4 (2020): 486-494.

[145] M. A. Askar, G. S. El-Sayyad, M. S. Guida, E. Khalifa, E. S. Shabana, and I. Y. Abdelrahman, “Amygdalin-folic Acid-nanoparticles Inhibit the Proliferation of Breast Cancer and Enhance the Effect of Radiotherapy Through the Modulation of Tumor-promoting Factors/Immunosuppressive Modulators in Vitro,” BMC Complementary Medicine and Therapies 23, no. 1 (2023): 162.

[146] N. Dechsupa, J. Kantapan, M. Tungjai, and I. S. Maprang, ““Bouea Macrophylla Griffith” Seeds: Proximate Composition, HPLC Fingerprint, and Antioxidation, Anticancer and Antimicrobial Properties of Ethanolic Seed Extracts,” Heliyon 5, no. 7 (2019): e02052.

[147] J. Kantapan, S. Paksee, A. Duangya, et al., “A Radiosensitizer, Gallotannin-rich Extract From Bouea Macrophylla Seeds, Inhibits Radiation-induced Epithelial-mesenchymal Transition in Breast Cancer Cells,” BMC Complementary Medicine and Therapies 21, no. 1 (2021): 189.

[148] N. Sisin, N. Mat, R. A. Rashid, et al., “Natural Baicalein-Rich Fraction as Radiosensitizer in Combination With Bismuth Oxide Nanoparticles and Cisplatin for Clinical Radiotherapy,” International Journal of Nanomedicine 17 (2022): 3853-3874.

[149] X. Ding, Q. Yang, X. Kong, B. G. Haffty, S. Gao, and M. S. Moran, “Radiosensitization Effect of Huaier on Breast Cancer Cells,” Oncology Reports 35, no. 5 (2016): 2843-2850.

[150] D. Kashyap, H. S. Tuli, M. B. Yerer, et al., “Natural Product-based Nanoformulations for Cancer Therapy: Opportunities and Challenges,” Seminars in Cancer Biology 69 (2021): 5-23.

[151] H. Nosrati, J. Charmi, F. Abhari, et al., “Improved Synergic Therapeutic Effects of Chemoradiation Therapy With the Aid of a co-drug-loaded Nano-radiosensitizer Under Conventional-dose X-ray Irradiation,” Biomaterials Science 8, no. 15 (2020): 4275-4286.

[152] Y. Liu, P. Zhang, F. Li, et al., “Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells,” Theranostics 8, no. 7 (2018): 1824-1849.

[153] Y. Kuang, Y. Zhang, Y. Zhao, et al., “Dual-Stimuli-Responsive Multifunctional Gd(2)Hf(2)O(7) Nanoparticles for MRI-Guided Combined Chemo-/Photothermal-/Radiotherapy of Resistant Tumors,” ACS Appl Mater Interfaces 12, no. 32 (2020): 35928-35939.

[154] C. Wu, X. Du, B. Jia, et al., “A Transformable Gold Nanocluster Aggregate-based Synergistic Strategy for Potentiated Radiation/Gene Cancer Therapy,” Journal of Materials Chemistry B 9, no. 9 (2021): 2314-2322.

[155] B. L. Cline, W. Jiang, C. Lee, et al., “Potassium Iodide Nanoparticles Enhance Radiotherapy Against Breast Cancer by Exploiting the Sodium-Iodide Symporter,” ACS Nano 15, no. 11 (2021): 17401-17411.

[156] H. Nosrati, M. Ghaffarlou, M. Salehiabar, et al., “Magnetite and Bismuth Sulfide Janus Heterostructures as Radiosensitizers for in Vivo Enhanced Radiotherapy in Breast Cancer,” Biomaterials Advances 140 (2022): 213090.

[157] R. Lu, D. Yang, D. Cui, Z. Wang, and L. Guo, “Egg White-mediated Green Synthesis of Silver Nanoparticles With Excellent Biocompatibility and Enhanced Radiation Effects on Cancer Cells,” International Journal of Nanomedicine 7 (2012): 2101-2107.

[158] J. Swanner, J. Mims, D. L. Carroll, et al., “Differential Cytotoxic and Radiosensitizing Effects of Silver Nanoparticles on Triple-negative Breast Cancer and Non-triple-negative Breast Cells,” International Journal of Nanomedicine 10 (2015): 3937-3953.

[159] F. K. Huang, W. C. Chen, S. F. Lai, et al., “Enhancement of Irradiation Effects on Cancer Cells by Cross-linked Dextran-coated Iron Oxide (CLIO) Nanoparticles,” Physics in Medicine and Biology 55, no. 2 (2010): 469-482.

[160] Y. W. Jiang, G. Gao, H. R. Jia, et al., “Copper Oxide Nanoparticles Induce Enhanced Radiosensitizing Effect via Destructive Autophagy,” ACS Biomaterials Science & Engineering 5, no. 3 (2019): 1569-1579.

[161] A. Meidanchi, “Mg((1-x))Cu(x)Fe(2)O(4) Superparamagnetic Nanoparticles as Nano-radiosensitizer Agents in Radiotherapy of MCF-7 human Breast Cancer Cells,” Nanotechnology 31, no. 32 (2020): 325706.

[162] N. Asadi, M. Gharbavi, H. Rezaeejam, A. Farajollahi, and B. Johari, “Zinc Nanoparticles Coated With Doxorubicin-conjugated Alginate as a Radiation Sensitizer in Triple-negative Breast Cancer Cells,” International Journal of Pharmaceutics 659 (2024): 124285.

[163] N. Igaz, K. Szőke, D. Kovács, et al., “Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures,” Nanomaterials (Basel) 10, no. 1 (2020): 158.

[164] A. Tudda, E. Donzelli, G. Nicolini, et al., “Breast Radiotherapy With Kilovoltage Photons and Gold Nanoparticles as Radiosensitizer: An in Vitro Study,” Medical Physics 49, no. 1 (2022): 568-578.

[165] H. Nosrati, M. Salehiabar, J. Charmi, et al., “Enhanced in Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles,” ACS Applied Bio Materials 6, no. 2 (2023): 784-792.

[166] M. A. Askar, N. M. Thabet, G. S. El-Sayyad, et al., “Dual Hyaluronic Acid and Folic Acid Targeting pH-Sensitive Multifunctional 2DG@DCA@MgO-Nano-Core-Shell-Radiosensitizer for Breast Cancer Therapy,” Cancers (Basel) 13, no. 21 (2021): 5571.

[167] Y. Zhang, D. Liu, B. Qiao, et al., “Bi-DTPA, a Potential CT-guided Radiation Sensitizer,” Biochemical and Biophysical Research Communications 671 (2023): 192-199.

[168] G. Chen, D. Jiang, S. Ding, C. Huang, D. Zhu, and H. Jiang, “A Tumor Cell Exosome-mimicking Multifunctional Nanozyme for Targeted Breast Cancer Radiotherapy,” Nanoscale 15, no. 36 (2023): 14949-14957.

[169] W. Liu, B. Chen, H. Zheng, et al., “Advances of Nanomedicine in Radiotherapy,” Pharmaceutics 13, no. 11 (2021): 1757.

[170] E. J. Moding, M. B. Kastan, and D. G. Kirsch, “Strategies for Optimizing the Response of Cancer and Normal Tissues to Radiation,” Nature Reviews Drug Discovery 12, no. 7 (2013): 526-542.

[171] A. C. Begg, F. A. Stewart, and C. Vens, “Strategies to Improve Radiotherapy With Targeted Drugs,” Nature Reviews Cancer 11, no. 4 (2011): 239-253.

[172] G. G. Steel, T. J. McMillan, and J. H. Peacock, “The 5Rs of Radiobiology,” International Journal of Radiation Biology 56, no. 6 (1989): 1045-1048.

[173] J. Zhang, L. Shen, and L. Q. Sun, “The Regulation of Radiosensitivity by p53 and Its Acetylation,” Cancer Letters 363, no. 2 (2015): 108-118.

[174] K. Camphausen and P. J. Tofilon, “Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization,” Journal of Clinical Oncology 25, no. 26 (2007): 4051-4056.

[175] G. O. Janssens, S. E. Rademakers, C. H. Terhaard, et al., “Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial,” Journal of Clinical Oncology 30, no. 15 (2012): 1777-1783.

[176] X. Chen, J. Zheng, M. L. Zhuo, A. Zhang, and Z. You, “A Six-gene-based Signature for Breast Cancer Radiotherapy Sensitivity Estimation,” Bioscience Reports 40, no. 12 (2020): BSR20202376.

[177] J. Zhang, N. Wu, T. Zhang, et al., “The Value of FATS Expression in Predicting Sensitivity to Radiotherapy in Breast Cancer,” Oncotarget 8, no. 24 (2017): 38491-38500.

[178] Z. Hu, G. Huang, A. Sadanandam, et al., “The Expression Level of HJURP Has an Independent Prognostic Impact and Predicts the Sensitivity to Radiotherapy in Breast Cancer,” Breast Cancer Research 12, no. 2 (2010): R18.

[179] L. Yu, Y. Yang, J. Hou, et al., “MicroRNA-144 Affects Radiotherapy Sensitivity by Promoting Proliferation, Migration and Invasion of Breast Cancer Cells,” Oncology Reports 34, no. 4 (2015): 1845-1852.

[180] T. Jiang, J. Chen, Z. Wang, et al., “miR-4796 Enhances the Sensitivity of Breast Cancer Cells to Ionising Radiation by Impairing the DNA Repair Pathway,” Breast Cancer (Tokyo, Japan) 30, no. 5 (2023): 691-702.

[181] E. Abdollahi and H. Mozdarani, “Epigenetic Regulation of Circ-HIPK3, Circ-PVT1, miR-25, and miR-149 in Radiosensitivity of Breast Cancer,” Experimental and Molecular Pathology 132-133 (2023): 104865.

[182] B. Wang, J. Zheng, R. Li, et al., “Long Noncoding RNA LINC02582 Acts Downstream of miR-200c to Promote Radioresistance Through CHK1 in Breast Cancer Cells,” Cell Death & Disease 10, no. 10 (2019): 764.

[183] N. Aoyama, Y. Ogawa, M. Yasuoka, et al., “Therapeutic Response to a Novel Enzyme-targeting Radiosensitization Treatment (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in Patients With Recurrent Breast Cancer,” Oncology Letters 12, no. 1 (2016): 29-34.

[184] N. Aoyama, Y. Ogawa, M. Yasuoka, et al., “Therapeutic Response to a Novel Enzyme-targeting Radiosensitization Treatment (KORTUC II) for Residual Lesions in Patients With Stage IV Primary Breast Cancer, Following Induction Chemotherapy With Epirubicin and Cyclophosphamide or Taxane,” Oncology Letters 13, no. 1 (2017): 69-76.

[185] T. Shimbo, M. Nakata, H. Yoshioka, et al., “New Enzyme-targeting Radiosensitizer (KORTUC II) Treatment for Locally Advanced or Recurrent Breast Cancer,” Molecular and Clinical Oncology 15, no. 5 (2021): 241.

[186] T. Shimbo, K. Yoshida, M. Nakata, et al., “KORTUC, a Novel Hydrogen Peroxide‑Based Radiosensitizer for the Enhancement of Brachytherapy in Patients With Unresectable Recurrent Uterine Cervical Cancer,” Oncology Letters 26, no. 3 (2023): 378.

[187] S. Obata, Y. Ishimaru, S. Miyagi, et al., “Actual Practice of Kochi Oxydol Radiation Therapy for Unresectable Carcinomas by Intra-tumoral Administration of Hydrogen Peroxide as a Radiosensitizer,” Molecular and Clinical Oncology 16, no. 3 (2022): 68.

[188] M. Nakata, K. Yoshida, T. Shimbo, et al., “High-dose-rate Interstitial Brachytherapy With Hypoxic Radiosensitizer KORTUC II for Unresectable Pelvic Sidewall Recurrence of Uterine Cervical Cancer: A Case Report,” Journal of Contemporary Brachytherapy 12, no. 6 (2020): 606-611.

[189] S. Dische, “Chemical Sensitizers for Hypoxic Cells: A Decade of Experience in Clinical Radiotherapy,” Radiotherapy and Oncology 3, no. 2 (1985): 97-115.

[190] J. H. Suh, “Efaproxiral: A Novel Radiation Sensitiser,” Expert Opinion on Investigational Drugs 13, no. 5 (2004): 543-550.

[191] L. A. Dunn, N. Riaz, M. G. Fury, et al., “A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent With Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma,” International Journal of Radiation and Oncology in Biology and Physics 106, no. 3 (2020): 564-570.

[192] J. M. Wilson, E. Fokas, S. J. Dutton, et al., “ARCII: A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Combination With Chemoradiation for Locally Advanced Inoperable Pancreatic Cancer,” Radiotherapy and Oncology 119, no. 2 (2016): 306-311.

[193] W. Tian, S. Hao, L. Wang, Y. Chen, Z. Li, and D. Luo, “Pyrotinib Treatment Enhances the Radiosensitivity in HER2-positive Brain Metastatic Breast Cancer Patients,” Anti-Cancer Drugs 33, no. 1 (2022): e622-e627.

[194] C. Strell, D. Folkvaljon, E. Holmberg, et al., “High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS Within the SweDCIS Randomized Trial,” Clinical Cancer Research 27, no. 12 (2021): 3469-3477.

[195] T. Hasegawa, M. Someya, M. Hori, et al., “Expression of Ku70 Predicts Results of Radiotherapy in Prostate Cancer,” Strahlentherapie Und Onkologie 193, no. 1 (2017): 29-37.

[196] P. Gong, T. Zhang, D. He, and J. T. Hsieh, “MicroRNA-145 Modulates Tumor Sensitivity to Radiation in Prostate Cancer,” Radiation Research 184, no. 6 (2015): 630-638.

[197] S. Skiöld, O. Azimzadeh, J. Merl-Pham, et al., “Unique Proteomic Signature for Radiation Sensitive Patients; a Comparative Study Between Normo-sensitive and Radiation Sensitive Breast Cancer Patients,” Mutation Research 776 (2015): 128-135.

[198] Q. Zhang, F. Qian, M. Cai, et al., “Research Progress on Factors Affecting the Sensitivity of Breast Cancer to Radiotherapy: A Narrative Review,” Translational Cancer Research 13, no. 7 (2024): 3869-3888.

[199] D. Valiyaveettil, D. Joseph, and M. Malik, “Cardiotoxicity in Breast Cancer Treatment: Causes and Mitigation,” Cancer Treatment and Research Communications 37 (2023): 100760.

[200] D. R. Florescu and D. E. Nistor, “Therapy-induced Cardiotoxicity in Breast Cancer Patients: A Well-known yet Unresolved Problem,” Discoveries (Craiova) 7, no. 1 (2019): e89.

[201] S. C. Darby, P. McGale, C. W. Taylor, and R. Peto, “Long-term Mortality From Heart Disease and Lung Cancer After Radiotherapy for Early Breast Cancer: Prospective Cohort Study of About 300,000 Women in US SEER Cancer Registries,” The Lancet Oncology 6, no. 8 (2005): 557-565.

[202] M. J. Hooning, B. M. Aleman, A. J. van Rosmalen, M. A. Kuenen, J. G. Klijn, and F. E. van Leeuwen, “Cause-specific Mortality in Long-term Survivors of Breast Cancer: A 25-year Follow-up Study,” International Journal of Radiation and Oncology in Biology and Physics 64, no. 4 (2006): 1081-1091.

[203] S. C. Darby, M. Ewertz, P. McGale, et al., “Risk of Ischemic Heart Disease in Women After Radiotherapy for Breast Cancer,” New England Journal of Medicine 368, no. 11 (2013): 987-998.

[204] A. K. Holley, L. Miao, D. K. St Clair, and W. H. St Clair, “Redox-modulated Phenomena and Radiation Therapy: The central Role of Superoxide Dismutases,” Antioxid Redox Signaling 20, no. 10 (2014): 1567-1589.

[205] C. Jaworski, J. A. Mariani, G. Wheeler, and D. M. Kaye, “Cardiac Complications of Thoracic Irradiation,” Journal of the American College of Cardiology 61, no. 23 (2013): 2319-2328.

[206] B. M. Aleman, E. C. Moser, J. Nuver, et al., “Cardiovascular Disease After Cancer Therapy,” European Journal of Cancer Supplements 12, no. 1 (2014): 18-28.

[207] I. J. Boero, A. J. Paravati, D. P. Triplett, et al., “Modern Radiation Therapy and Cardiac Outcomes in Breast Cancer,” International Journal of Radiation and Oncology in Biology and Physics 94, no. 4 (2016): 700-708.

[208] B. Welsh, M. Chao, and F. Foroudi, “Reducing Cardiac Doses: A Novel Multi-leaf Collimator Modification Technique to Reduce Left Anterior Descending Coronary Artery Dose in Patients With Left-sided Breast Cancer,” Journal of Medical Radiation Sciences 64, no. 2 (2017): 114-119.

[209] M. E. Mast, L. van Kempen-Harteveld, M. W. Heijenbrok, et al., “Left-sided Breast Cancer Radiotherapy With and Without Breath-hold: Does IMRT Reduce the Cardiac Dose Even Further,” Radiotherapy and Oncology 108, no. 2 (2013): 248-253.

[210] S. O. Osman, S. Hol, P. M. Poortmans, and M. Essers, “Volumetric Modulated Arc Therapy and Breath-hold in Image-guided Locoregional Left-sided Breast Irradiation,” Radiotherapy and Oncology 112, no. 1 (2014): 17-22.

[211] S. L. Gaytan, E. Beaven, S. S. Gadad, and M. Nurunnabi, “Progress and Prospect of Nanotechnology for Cardiac Fibrosis Treatment,” Interdisciplinary Medicine 1, no. 4 (2023): e20230018.

[212] S. Darby, P. McGale, C. Correa, et al., “Effect of Radiotherapy After Breast-conserving Surgery on 10-year Recurrence and 15-year Breast Cancer Death: Meta-analysis of Individual Patient Data for 10,801 Women in 17 Randomised Trials,” Lancet 378, no. 9804 (2011): 1707-1716.

[213] Y. Oie, Y. Saito, M. Kato, et al., “Relationship Between Radiation Pneumonitis and Organizing Pneumonia After Radiotherapy for Breast Cancer,” Radiation Oncology 8 (2013): 56.

[214] P. Mehnati, M. Ghorbanipoor, M. Mohammadzadeh, B. Nasiri Motlagh, and A. Mesbahi, “Predicting the Risk of Radiation Pneumonitis and Pulmonary Function Changes After Breast Cancer Radiotherapy,” Journal of Biomedical Physics and Engineering 11, no. 4 (2021): 459-464.

[215] J. T. Ma, Y. Liu, L. Sun, et al., “Chest Wall Toxicity after Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies,” International Journal of Radiation and Oncology in Biology and Physics 103, no. 4 (2019): 843-850.

[216] D. L. Andolino, J. A. Forquer, M. A. Henderson, et al., “Chest Wall Toxicity After Stereotactic Body Radiotherapy for Malignant Lesions of the Lung and Liver,” International Journal of Radiation and Oncology in Biology and Physics 80, no. 3 (2011): 692-697.

[217] N. Pettersson, J. Nyman, and K. A. Johansson, “Radiation-induced Rib Fractures After Hypofractionated Stereotactic Body Radiation Therapy of Non-small Cell Lung Cancer: A Dose- and Volume-response Analysis,” Radiotherapy and Oncology 91, no. 3 (2009): 360-368.

[218] N. E. Dunlap, J. Cai, G. B. Biedermann, et al., “Chest Wall Volume Receiving >30 Gy Predicts Risk of Severe Pain and/or Rib Fracture After Lung Stereotactic Body Radiotherapy,” International Journal of Radiation and Oncology in Biology and Physics 76, no. 3 (2010): 796-801.

[219] M. Pandey, K. N. Chandramohan, and A. Mathew, “An Unusual Lesion on the Chest Wall,” International Wound Journal 1, no. 2 (2004): 152-154.

[220] R. Arya, W. T. Chow, W. M. Rozen, et al., “Microsurgical Reconstruction of Large Oncologic Chest Wall Defects for Locally Advanced Breast Cancer or Osteoradionecrosis: A Retrospective Review of 26 Cases Over a 5-Year Period,” Journal of Reconstructive Microsurgery 32, no. 2 (2016): 121-127.

[221] S. Kim and Y. S. Kim, “Radiation-induced Osteoradionecrosis of the Ribs in a Patient With Breast Cancer: A Case Report,” Radiology Case Reports 17, no. 8 (2022): 2894-2898.

[222] A. Latrèche, V. Bourbonne, and F. Lucia, “Unrecognized Thoracic Radiotherapy Toxicity: A Review of Literature,” Cancer Radiotherapie 26, no. 4 (2022): 616-621.

[223] S. K. Al-Ghazal, L. Fallowfield, and R. W. Blamey, “Does Cosmetic Outcome From Treatment of Primary Breast Cancer Influence Psychosocial Morbidity,” European Journal of Surgical Oncology 25, no. 6 (1999): 571-573.

[224] D. Azria, O. Riou, F. Castan, et al., “Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis after Radiotherapy: Results of the Prospective Multicenter French Trial,” EBioMedicine 2, no. 12 (2015): 1965-1973.

[225] S. Pereira, L. Bodgi, M. Duclos, et al., “Fast and Binary Assay for Predicting Radiosensitivity Based on the Theory of ATM Nucleo-Shuttling: Development, Validation, and Performance,” International Journal of Radiation and Oncology in Biology and Physics 100, no. 2 (2018): 353-360.

[226] A. N. McMahon, E. Lee, C. Takita, I. M. Reis, J. L. Wright, and J. J. Hu, “Metabolomics in Radiotherapy-Induced Early Adverse Skin Reactions of Breast Cancer Patients,” Breast Cancer (Dove Med Press) 16 (2024): 369-377.

[227] J. L. Rodriguez-Gil, C. Takita, J. Wright, et al., “Inflammatory Biomarker C-reactive Protein and Radiotherapy-induced Early Adverse Skin Reactions in Patients With Breast Cancer,” Cancer Epidemiology and Prevention Biomarkers 23, no. 9 (2014): 1873-1883.

[228] B. A. Jereczek-Fossa, H. R. Marsiglia, and R. Orecchia, “Radiotherapy-related Fatigue,” Critical Reviews in Oncology/Hematology 41, no. 3 (2002): 317-325.

[229] L. Kowalczyk, C. Deutschmann, R. Crevenna, S. Konrad, C. F. Singer, and A. Farr, “Radiotherapy-Induced Fatigue in Breast Cancer Patients,” Breast Care (Basel) 16, no. 3 (2021): 236-242.

[230] K. S. Manir, K. Bhadra, G. Kumar, A. Manna, N. B. Patra, and S. K. Sarkar, “Fatigue in Breast Cancer Patients on Adjuvant Treatment: Course and Prevalence,” Indian Journal of Palliative Care 18, no. 2 (2012): 109-116.

[231] S. Blair, W. A. Bardwell, Y. Podbelewicz-Schuller, and J. E. Mortimer, “Correlation Between Hemoglobin and Fatigue in Women Undergoing Adjuvant Chemotherapy Without Erythropoietin-stimulating-agent Support,” Clinical Breast Cancer 8, no. 6 (2008): 522-526.

[232] C. Wratten, J. Kilmurray, S. Nash, et al., “Fatigue During Breast Radiotherapy and Its Relationship to Biological Factors,” International Journal of Radiation and Oncology in Biology and Physics 59, no. 1 (2004): 160-167.

[233] E. I. Azzam, J. P. Jay-Gerin, and D. Pain, “Ionizing Radiation-induced Metabolic Oxidative Stress and Prolonged Cell Injury,” Cancer Letters 327, no. 1-2 (2012): 48-60.

[234] M. Lind, C. Vernon, D. Cruickshank, et al., “The Level of Haemoglobin in Anaemic Cancer Patients Correlates Positively With Quality of Life,” British Journal of Cancer 86, no. 8 (2002): 1243-1249.

[235] A. M. Berger, K. Mooney, A. Alvarez-Perez, et al., “Cancer-Related Fatigue, Version 2.2015,” Journal of the National Comprehensive Cancer Network: JNCCN 13, no. 8 (2015): 1012-1039.

[236] A. M. Berger, A. P. Abernethy, A. Atkinson, et al., “Clinical Practice Guidelines Cancer-related Fatigue,” Journal of the National Comprehensive Cancer Network: JNCCN 8, no. 8 (2010): 904-931.

[237] C. Salata, C. E. deAlmeida, S. C. Ferreira-Machado, et al., “Preliminary Pre-clinical Studies on the Side Effects of Breast Cancer Treatment,” International Journal of Radiation Biology 97, no. 7 (2021): 877-887.

[238] G. Kareliotis, I. Tremi, M. Kaitatzi, et al., “Combined Radiation Strategies for Novel and Enhanced Cancer Treatment,” International Journal of Radiation Biology 96, no. 9 (2020): 1087-1103.

[239] L. J. Forker, A. Choudhury, and A. E. Kiltie, “Biomarkers of Tumour Radiosensitivity and Predicting Benefit From Radiotherapy,” Clinical Oncology (Royal College of Radiologists (Great Britain)) 27, no. 10 (2015): 561-569.

[240] M. Sjöström, A. Fyles, F. F. Liu, et al., “Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer,” Journal of Clinical Oncology 41, no. 8 (2023): 1533-1540.

[241] I. Fredriksson, G. Liljegren, M. Palm-Sjövall, et al., “Risk Factors for Local Recurrence After Breast-conserving Surgery,” British Journal of Surgery 90, no. 9 (2003): 1093-1102.

[242] Y. Cui, B. Li, E. L. Pollom, K. C. Horst, and R. Li, “Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer,” Clinical Cancer Research 24, no. 19 (2018): 4754-4762.

[243] M. Sjöström, S. L. Chang, N. Fishbane, et al., “Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment after Breast-Conserving Surgery for Early-Stage Breast Cancer,” Journal of Clinical Oncology 37, no. 35 (2019): 3340-3349.

[244] T. Tramm, H. Mohammed, S. Myhre, et al., “Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients With High-risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort,” Clinical Cancer Research 20, no. 20 (2014): 5272-5280.

[245] K. S. Albain, W. E. Barlow, S. Shak, et al., “Prognostic and Predictive Value of the 21-gene Recurrence Score Assay in Postmenopausal Women With Node-positive, Oestrogen-receptor-positive Breast Cancer on Chemotherapy: A Retrospective Analysis of a Randomised Trial,” The Lancet Oncology 11, no. 1 (2010): 55-65.

[246] M. Dowsett, J. Cuzick, C. Wale, et al., “Prediction of Risk of Distant Recurrence Using the 21-gene Recurrence Score in Node-negative and Node-positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study,” Journal of Clinical Oncology 28, no. 11 (2010): 1829-1834.

[247] M. Dowsett, I. Sestak, E. Lopez-Knowles, et al., “Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy,” Journal of Clinical Oncology 31, no. 22 (2013): 2783-2790.

[248] J. A. Sparano, R. J. Gray, D. F. Makower, et al., “Prospective Validation of a 21-Gene Expression Assay in Breast Cancer,” New England Journal of Medicine 373, no. 21 (2015): 2005-2014.

[249] S. Paik, S. Shak, G. Tang, et al., “A Multigene Assay to Predict Recurrence of Tamoxifen-treated, Node-negative Breast Cancer,” New England Journal of Medicine 351, no. 27 (2004): 2817-2826.

[250] A. N. Neagu, D. Whitham, E. Buonanno, et al., “Proteomics and Its Applications in Breast Cancer,” American Journal of Cancer Research 11, no. 9 (2021): 4006-4049.

[251] W. B. Coleman, “Next-Generation Breast Cancer Omics,” American Journal of Pathology 187, no. 10 (2017): 2130-2132.

[252] C. Davatzikos, S. Rathore, S. Bakas, et al., “Cancer Imaging Phenomics Toolkit: Quantitative Imaging Analytics for Precision Diagnostics and Predictive Modeling of Clinical Outcome,” Journal of Medical Imaging (Bellingham) 5, no. 1 (2018): 011018.

[253] M. Shahani, J. Shakeri, M. E. Akbari, et al., “Transcriptomic and Proteomic Approaches Reveal Biological Basis of Intraoperative Radiotherapy-treated Tumor Bed Modification in Breast Cancer Patients: A Pilot Study,” Journal of Proteomics 212 (2020): 103596.

[254] A. Boire, P. K. Brastianos, L. Garzia, and M. Valiente, “Brain Metastasis,” Nature Reviews Cancer 20, no. 1 (2020): 4-11.

[255] L. Koniali, A. Hadjisavvas, A. Constantinidou, et al., “Risk Factors for Breast Cancer Brain Metastases: A Systematic Review,” Oncotarget 11, no. 6 (2020): 650-669.

[256] A. Darlix, G. Louvel, J. Fraisse, et al., “Impact of Breast Cancer Molecular Subtypes on the Incidence, Kinetics and Prognosis of central Nervous System Metastases in a Large Multicentre Real-life Cohort,” British Journal of Cancer 121, no. 12 (2019): 991-1000.

[257] F. Arshad, L. Wang, C. Sy, S. Avraham, and H. K. Avraham, “Blood-brain Barrier Integrity and Breast Cancer Metastasis to the Brain,” Pathology Research International 2011 (2010): 920509.

[258] L. Terceiro, N. M. Ikeogu, M. F. Lima, et al., “Navigating the Blood-Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases,” International Journal of Molecular Sciences 24, no. 15 (2023): 12034.

[259] P. S. Steeg, “The Blood-tumour Barrier in Cancer Biology and Therapy,” Nature reviews Clinical oncology 18, no. 11 (2021): 696-714.

[260] Y. Liang, H. Zhang, X. Song, and Q. Yang, “Metastatic Heterogeneity of Breast Cancer: Molecular Mechanism and Potential Therapeutic Targets,” Seminars in Cancer Biology 60 (2020): 14-27.

[261] S. Amin, M. J. Baine, J. L. Meza, and C. Lin, “Association of Immunotherapy with Survival among Patients with Brain Metastases whose Cancer Was Managed with Definitive Surgery of the Primary Tumor,” JAMA Network Open 3, no. 9 (2020): e2015444.

[262] K. Niesel, M. Schulz, J. Anthes, et al., “The Immune Suppressive Microenvironment Affects Efficacy of Radio-immunotherapy in Brain Metastasis,” EMBO Molecular Medicine 13, no. 5 (2021): e13412.

[263] S. Kotb, A. Detappe, F. Lux, et al., “Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept Before Phase I Trial,” Theranostics 6, no. 3 (2016): 418-427.

[264] C. Verry, S. Dufort, B. Lemasson, et al., “Targeting Brain Metastases With Ultrasmall Theranostic Nanoparticles, a First-in-human Trial From an MRI Perspective,” Science Advances 6, no. 29 (2020): eaay5279.

[265] R. Stupp, M. E. Hegi, W. P. Mason, et al., “Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-year Analysis of the EORTC-NCIC Trial,” The Lancet Oncology 10, no. 5 (2009): 459-466.

[266] T. Lautenschlaeger, J. Perry, D. Peereboom, et al., “In Vitro Study of Combined Cilengitide and Radiation Treatment in Breast Cancer Cell Lines,” Radiation Oncology 8 (2013): 246.

[267] W. H. Chae, K. Niesel, M. Schulz, et al., “Evaluating Magnetic Resonance Spectroscopy as a Tool for Monitoring Therapeutic Response of Whole Brain Radiotherapy in a Mouse Model for Breast-to-Brain Metastasis,” Frontiers in Oncology 9 (2019): 1324.

[268] R. L. Bowman, F. Klemm, L. Akkari, et al., “Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies,” Cell Reports 17, no. 9 (2016): 2445-2459.

[269] K. A. Kyei, J. Daniels, F. Pratt-Ainooson, et al., “Incidence and Severity of Acute Radiation Induced Toxicities Among Breast Cancer Patients Treated With Adjuvant Radiotherapy at a Major Cancer Treatment Center in Ghana,” Translational Oncology 47 (2024): 102032.

[270] H. K. Jandu, C. D. Veal, L. Fachal, et al., “Genome-wide Association Study of Treatment-related Toxicity Two Years Following Radiotherapy for Breast Cancer,” Radiotherapy and Oncology 187 (2023): 109806.

[271] Y. Xie, Y. Han, X. Zhang, et al., “Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma,” Frontiers in Oncology 11 (2021): 633827.

[272] S. Li, Z. Jian, W. Zhengming, et al., “Downregulated lncRNA DRAIC Enhances the Radiotherapy Sensitivity of human HCC Cell Line HepG2 by Targeting miR-223-3p,” Oncology and Translational Medicine 8, no. 6 (2022): 293-300.

[273] A. Yang, N.a Lu, H. Jiang, et al., “Automatic Delineation of Organs at Risk in Non-small Cell Lung Cancer Radiotherapy Based on Deep Learning Networks*,” Oncology and Translational Medicine 8, no. 2 (2022): 83-88.

[274] L. Zhao and W. Luhua, “Advancements in Radiotherapy for Lung Cancer in China. February 2015,” Oncology and Translational Medicine 1, no. 1 (2015): 5-14.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.